Home/Database/CagriSema
MetabolicPhase III Trials

CagriSema

Cagrilintide + Semaglutide Combination

Ask AI About This

Amino Acids

N/A

Molecular Weight

Combination product

Half-life

~7 days (both components)

Research Score

4.5

Studies

38

Storage

N/A

What is CagriSema?

CagriSema is a fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide (GLP-1 agonist). By targeting two complementary satiety pathways, it achieves superior weight loss compared to either component alone. Phase III trials show it may become the most effective obesity treatment.

Key Benefits & Mechanisms

Superior weight loss to semaglutide alone

Dual satiety pathway activation

Amylin + GLP-1 synergy

Up to 25% weight loss in trials

Improved glycemic control

Reduced food cravings

Once-weekly injection

Research Summary

CagriSema Phase II results showed approximately 15-17% weight loss over 32 weeks, with Phase III REDEFINE trials ongoing showing potentially higher efficacy at full dose. Novo Nordisk expects this to be their next-generation obesity treatment following Wegovy.

Related Peptides

Semaglutide

GLP-1 Receptor Agonist

Semaglutide is a GLP-1 receptor agonist with proven efficacy for weight management and glycemic control. FDA-approved as Ozempic (diabetes) and Wegovy (weight management), it mimics the incretin hormone GLP-1 to regulate appetite and blood sugar.

Metabolic

Tirzepatide

GIP/GLP-1 Dual Receptor Agonist

Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight management). It offers superior weight loss compared to GLP-1-only agonists by targeting two incretin pathways simultaneously.

Metabolic

AOD-9604

Anti-Obesity Drug (Modified GH Fragment)

AOD-9604 is a modified fragment of human growth hormone (HGH fragment 177-191) specifically designed for fat metabolism. It stimulates lipolysis and inhibits lipogenesis without affecting blood sugar or tissue growth, making it a targeted fat-loss peptide without typical GH side effects.

Metabolic

Tesamorelin

Synthetic Growth Hormone Releasing Hormone

Tesamorelin is an FDA-approved synthetic analog of growth hormone-releasing hormone (GHRH). Approved as Egrifta for HIV-associated lipodystrophy, it reduces visceral adipose tissue while maintaining peripheral fat and improving body composition. Produces physiological GH release.

Metabolic